IL218548A - A pharmaceutical preparation containing recombinant hcg - Google Patents

A pharmaceutical preparation containing recombinant hcg

Info

Publication number
IL218548A
IL218548A IL218548A IL21854812A IL218548A IL 218548 A IL218548 A IL 218548A IL 218548 A IL218548 A IL 218548A IL 21854812 A IL21854812 A IL 21854812A IL 218548 A IL218548 A IL 218548A
Authority
IL
Israel
Prior art keywords
pharmaceutical preparation
recombinant hcg
hcg
recombinant
pharmaceutical
Prior art date
Application number
IL218548A
Other languages
English (en)
Hebrew (he)
Other versions
IL218548A0 (en
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of IL218548A0 publication Critical patent/IL218548A0/en
Publication of IL218548A publication Critical patent/IL218548A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1081Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL218548A 2009-10-05 2012-03-08 A pharmaceutical preparation containing recombinant hcg IL218548A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05
PCT/GB2010/001854 WO2011042688A1 (en) 2009-10-05 2010-10-04 Pharmaceutical preparation comprising recombinant hcg

Publications (2)

Publication Number Publication Date
IL218548A0 IL218548A0 (en) 2012-05-31
IL218548A true IL218548A (en) 2017-03-30

Family

ID=41471027

Family Applications (3)

Application Number Title Priority Date Filing Date
IL218548A IL218548A (en) 2009-10-05 2012-03-08 A pharmaceutical preparation containing recombinant hcg
IL250733A IL250733B (en) 2009-10-05 2017-02-23 A pharmaceutical preparation containing recombinant hcg
IL267556A IL267556A (en) 2009-10-05 2019-06-20 A pharmaceutical preparation containing recombinant hcg

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL250733A IL250733B (en) 2009-10-05 2017-02-23 A pharmaceutical preparation containing recombinant hcg
IL267556A IL267556A (en) 2009-10-05 2019-06-20 A pharmaceutical preparation containing recombinant hcg

Country Status (25)

Country Link
US (5) US8975226B2 (index.php)
EP (2) EP2486051B1 (index.php)
JP (6) JP6176924B2 (index.php)
KR (7) KR20230012104A (index.php)
CN (1) CN107050434B (index.php)
AR (2) AR079876A1 (index.php)
AU (1) AU2010304922B2 (index.php)
BR (1) BR112012007990A2 (index.php)
CA (1) CA2776790A1 (index.php)
DK (1) DK2486051T3 (index.php)
ES (2) ES3036152T3 (index.php)
HR (1) HRP20200941T1 (index.php)
HU (1) HUE050793T2 (index.php)
IL (3) IL218548A (index.php)
IN (1) IN2012DN02073A (index.php)
JO (1) JOP20200039A1 (index.php)
LT (1) LT2486051T (index.php)
MX (1) MX2012003951A (index.php)
PL (1) PL2486051T3 (index.php)
PT (1) PT2486051T (index.php)
RS (1) RS60413B1 (index.php)
RU (2) RU2724528C2 (index.php)
SI (1) SI2486051T1 (index.php)
TW (2) TWI532495B (index.php)
WO (1) WO2011042688A1 (index.php)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
AR090095A1 (es) * 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
ES2784510T3 (es) 2012-12-10 2020-09-28 Seikagaku Kogyo Co Ltd Método para producir un nuevo Factor C recombinante, método para mitigar la inhibición de la reacción en ensayos de endotoxina, y método para medir endotoxina
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cmp依存性シアリダーゼ活性
MX389908B (es) * 2015-04-24 2025-03-20 Ferring Bv Metodo de produccion de gonadotrofina.
MY179524A (en) 2015-06-26 2020-11-10 Ferring Bv Methods of purification and/or viral inactivation
HUE071268T2 (hu) * 2018-04-30 2025-08-28 Ferring Bv Készítmény szabályozott petefészek-stimuláláshoz
IL295278A (en) * 2020-02-05 2022-10-01 Novartis Ag cho cell expressing heterodimers of il-15
CN116199742B (zh) * 2022-07-06 2025-01-24 华兰基因工程有限公司 一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) * 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
DE69524456T2 (de) * 1995-03-21 2002-08-01 Applied Research Systems Flüssige hcg-formulierungen
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
ES2268781T3 (es) 1997-06-25 2007-03-16 Applied Research Systems Ars Holding N.V. Analogos de hormonas glicoproteinicas reticuladas con disulfuro, su preparacion y uso.
US6500627B1 (en) 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
WO2003050286A1 (en) * 2001-10-29 2003-06-19 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US7304031B2 (en) * 2001-10-29 2007-12-04 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
HK1045261A1 (zh) 1999-05-07 2002-11-22 Laboratoires Serono S.A. 促性腺激素
ME00296B (me) 2000-02-22 2011-05-10 Applied Res Systems Ars Holding N V PROCES PREČIŠĆAVANJA hCG I REKOMBINANTNOG hCG PREČIŠĆENOG TOM METODOM
MXPA04002256A (es) 2001-09-12 2004-07-23 Applied Research Systems Uso de gonadotropina corionica humana (gch) en hiperestimulacion ovarica controlada.
PL369606A1 (en) * 2001-10-22 2005-05-02 Applied Research Systems Ars Holding N.V. Gonadotrophins for folliculogenesis
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
MXPA05010773A (es) * 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP4518464B2 (ja) 2003-06-30 2010-08-04 ミヨシ油脂株式会社 紙類処理剤及び紙類
US8017388B2 (en) * 2003-08-18 2011-09-13 Glycotope Gmbh Tumour cell lines and uses thereof
ES2350298T3 (es) * 2004-02-04 2011-01-20 Centre National De La Recherche Scientifique Procedimiento para el cribado de anticuerpos específicos de glicoforma.
CN103627670B (zh) * 2004-02-13 2016-12-21 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
KR20070110902A (ko) * 2005-03-11 2007-11-20 프레제니우스 카비 도이치란트 게엠베하 비활성 출발 물질로부터 생물활성 당단백질의 생산
WO2007022206A1 (en) * 2005-08-15 2007-02-22 Siemens Vdo Automotive Corporation Automotive diesel exhaust hc dosing valve
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 dna칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
WO2008011633A2 (en) * 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) * 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
TWI488640B (zh) * 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CA3163525A1 (en) * 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
CN102549011A (zh) 2012-07-04
ES3036152T3 (en) 2025-09-15
JP2021176867A (ja) 2021-11-11
US11292824B2 (en) 2022-04-05
IL250733A0 (en) 2017-04-30
US20130023476A1 (en) 2013-01-24
KR20210014767A (ko) 2021-02-09
RU2724528C2 (ru) 2020-06-23
RU2588650C2 (ru) 2016-07-10
KR101804479B1 (ko) 2017-12-05
US20180030107A1 (en) 2018-02-01
JP6580104B2 (ja) 2019-09-25
IL218548A0 (en) 2012-05-31
PL2486051T3 (pl) 2020-09-07
LT2486051T (lt) 2020-07-10
EP2486051B1 (en) 2020-03-25
US8975226B2 (en) 2015-03-10
BR112012007990A2 (pt) 2017-07-25
EP3611185B1 (en) 2025-04-30
EP2486051A1 (en) 2012-08-15
US10526390B2 (en) 2020-01-07
SI2486051T1 (sl) 2020-08-31
KR102489143B1 (ko) 2023-01-13
JP2023075144A (ja) 2023-05-30
TWI532495B (zh) 2016-05-11
TW201632198A (zh) 2016-09-16
JP7196244B2 (ja) 2022-12-26
RU2016118236A3 (index.php) 2019-09-18
AU2010304922B2 (en) 2014-11-06
AR079876A1 (es) 2012-02-29
RS60413B1 (sr) 2020-07-31
IN2012DN02073A (index.php) 2015-08-21
RU2012112907A (ru) 2013-11-10
JOP20200039A1 (ar) 2022-10-30
US20140249082A1 (en) 2014-09-04
HRP20200941T1 (hr) 2020-09-18
JP2016074680A (ja) 2016-05-12
MX2012003951A (es) 2012-05-29
CN107050434B (zh) 2021-07-27
WO2011042688A1 (en) 2011-04-14
KR20190028823A (ko) 2019-03-19
CN107050434A (zh) 2017-08-18
RU2016118236A (ru) 2018-10-29
ES2798258T3 (es) 2020-12-10
DK2486051T3 (da) 2020-06-22
JP6310440B2 (ja) 2018-04-11
PT2486051T (pt) 2020-06-17
AR125991A2 (es) 2023-08-30
US20200247863A1 (en) 2020-08-06
JP7292153B2 (ja) 2023-06-16
KR102213154B1 (ko) 2021-02-05
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
EP3611185A1 (en) 2020-02-19
KR20210141771A (ko) 2021-11-23
TW201113030A (en) 2011-04-16
US20220340634A1 (en) 2022-10-27
KR101987982B1 (ko) 2019-06-11
JP2020000246A (ja) 2020-01-09
US12234272B2 (en) 2025-02-25
CA2776790A1 (en) 2011-04-14
HUE050793T2 (hu) 2021-01-28
JP2013506708A (ja) 2013-02-28
KR20230012104A (ko) 2023-01-25
KR20170133531A (ko) 2017-12-05
AU2010304922A1 (en) 2012-03-29
IL267556A (en) 2019-08-29
US9676835B2 (en) 2017-06-13
KR20190067256A (ko) 2019-06-14
JP2018076296A (ja) 2018-05-17
JP6176924B2 (ja) 2017-08-09
IL250733B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
IL267556A (en) A pharmaceutical preparation containing recombinant hcg
SG175037A1 (en) Pharmaceutical composition
ZA201200719B (en) Pharmaceutical formulation
GB0909680D0 (en) Dosage form
EP2379077A4 (en) PHARMACEUTICAL COMPOSITION
IL220097A (en) Pharmaceutical preparation containing oligopeptides
PL2496596T3 (pl) Peptydy terapeutyczne
ZA201104348B (en) Pharmaceutical preparation
EP2480578A4 (en) MODIFICATION OF POLYPEPTIDE
GB0815972D0 (en) Pharmaceutical preparation
ZA201108446B (en) FViII-DERIVED PEPTIDES
ZA201203722B (en) Peptide
HRP20141173T1 (hr) Medikament koji sadrži miramistin
GB0922537D0 (en) Pharmaceutical preparation
GB0919650D0 (en) Pharmaceutical composition
GB0906971D0 (en) Pharmaceutical preparation
GB201115179D0 (en) Pharmaceutical preparation
GB201115173D0 (en) Pharmaceutical preparation
GB0910772D0 (en) Pharmaceutical
PL390620A1 (pl) Preparat farmaceutyczny
GB0909494D0 (en) Neuroprotective peptide
IL214496A0 (en) Short b-defensin-derived peptides
GB0903318D0 (en) Medicament
GB0901902D0 (en) Medicament
GB0911790D0 (en) Peptides

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed